Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the ...
Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la ...
Jean-Paul Kress to join Sanofi's Board of Directors Paris, . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, ...
We’re using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design, and improving the manufacturing and supply of medicines and vaccines to get them to ...
Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) Tolebrutinib is the first and only brain-penetrant BTK ...
Sanofi (“Sanofi") maintains this Website (the "Website") for your information, education and communication. Please feel free to browse the Website. Through your access and use of the Website, you ...
Alle Angaben unseres Internetangebotes wurden sorgfältig geprüft. Wir bemühen uns, dieses Informationsangebot stetig zu erweitern und zu aktualisieren. Eine Garantie für die Vollständigkeit, ...